FDA to assess drug for eyelashes
Federal regulators said a glaucoma drug from Allergan Inc. appears to make eyelashes longer and fuller, and experts soon will assess the safety of that new use.
The Irvine company has asked the Food and Drug Administration to approve its bimatoprost formula to enhance eyelashes. On Friday a panel of experts will comment on the drug’s safety and effectiveness as a cosmetic.
The drug is already marketed under the name Lumigan to treat eye conditions stemming from glaucoma. In studies for that treatment, researchers first noticed the drug seemed to stimulate eyelash growth.
Allergan plans to market the drug under the brand name Latisse if it is approved as a cosmetic treatment.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
